Recent advancements in AI and ML are revolutionizing scientific fields, especially model-informed drug discovery and development (MID3). The Innovation and Quality (IQ) Consortium's AI/ML working group promotes the acceptance of these technologies, and their white paper highlights applications in pharmacometrics, disease modeling, NLP, and drug discovery, as well as best practices for responsible AI use.
This white paper is open-access and published in Clinical Pharmacology & Therapeutics. Any comments, discussions, or published articles sharing experiences and thoughts would be highly appreciated.
Terranova N, Renard D, Shahin MH, Menon S, Cao Y, Hop CE, Hayes S, Madrasi K, Stodtmann S, Tensfeldt T, Vaddady P. Artificial intelligence for quantitative modeling in drug discovery and development: An innovation and quality consortium perspective on use cases and best practices. Clinical Pharmacology & Therapeutics. 2024 Apr;115(4):658-72.
------------------------------
Sudip Das, MPharm, PhD
Distinguished Faculty, Butler University
Professor of Pharmaceutics & Drug Delivery
4600 Sunset Avenue, Indianapolis, IN 46208-3485
E-mail:
[email protected]Webpage:
https://research.butler.edu/nanomedicine/LinkedIn:
http://www.linkedin.com/in/sudipkdasDisclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------